FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:840-844 September 16, 1993 Number 12 Next

	Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Patients with homozygous beta-thalassemia, who have a good prognosis during treatment with conventional therapy, appear to have an especially high probability of hematologic cure with bone marrow transplantation, although the morbidity and mortality associated with such treatment are not established.

Methods The records of all patients with thalassemia who received bone marrow transplants from HLA-identical donors in Pesaro, Italy, were examined from October 1982 through May 1992. Detailed evaluation of the outcome was conducted in the 89 patients identified as being in class 1 according to the Pesaro classification, in which hepatomegaly, portal fibrosis, and the inadequacy of iron chelation therapy are considered independent risk factors, and the patients are classified as being in class 1 if none of these factors are present, class 2 if one or two of the factors are present, and class 3 if all three factors are present. Sixty-four of the patients had been prepared for transplantation with a drug regimen in current use that includes busulfan and cyclophosphamide followed by cyclosporine as prophylaxis against acute graft-versus-host disease (protocol 6).

Results There were seven deaths, all within 101 days of transplantation. Two of the 64 patients treated according to protocol 6 died. The probabilities of survival, rejection-free survival, death from causes unrelated to rejection, and rejection were 0.92, 0.85, 0.06, and 0.08, respectively, in the total group and 0.97, 0.93, 0.03, and 0.04 in the 64 patients treated according to protocol 6. Preliminary evidence suggests that there was useful unloading of tissue iron deposits.

Conclusions The high probability of cure with little early or late morbidity and mortality suggests that patients with class 1 thalassemia who have HLA-identical donors available should be treated by bone marrow transplantation. However, this was not a controlled trial, so we cannot directly compare the outcome with that of conventional treatment.

Source Information

From the Divisione Ematologica e Centro Trapianto Midollo Osseo di Muraglia, Ospedale di Pesaro, Pesaro, Italy (G.L., M.G., P.P., E.A., D.B., C.G., M.A., F. Agostinelli, F. Albertini), and the Fred Hutchinson Cancer Research Center, Seattle (R.A.C.).

Address reprint requests to Mr. Clift at 2919 129th Ave. N.E., Seattle, WA 98104.

Full Text of this Article

This article has been cited by other articles:

• Armand, P., Kim, H. T., Cutler, C. S., Ho, V. T., Koreth, J., Alyea, E. P., Soiffer, R. J., Antin, J. H. (2007). Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 109: 4586-4588 [Abstract] [Full Text]  
• Fleischhauer, K., Locatelli, F., Zecca, M., Orofino, M. G., Giardini, C., De Stefano, P., Pession, A., Iannone, A. M., Carcassi, C., Zino, E., La Nasa, G. (2006). Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with nonpermissive HLA-DPB1 disparity in host-versus-graft direction. Blood 107: 2984-2992 [Abstract] [Full Text]  
• Locatelli, F. (2006). Reduced-Intensity Regimens in Allogeneic Hematopoietic Stem Cell Transplantation for Hemoglobinopathies. ASH Education Book 2006: 398-401 [Abstract] [Full Text]  
• Locatelli, F., Rocha, V., Reed, W., Bernaudin, F., Ertem, M., Grafakos, S., Brichard, B., Li, X., Nagler, A., Giorgiani, G., Haut, P. R., Brochstein, J. A., Nugent, D. J., Blatt, J., Woodard, P., Kurtzberg, J., Rubin, C. M., Miniero, R., Lutz, P., Raja, T., Roberts, I., Will, A. M., Yaniv, I., Vermylen, C., Tannoia, N., Garnier, F., Ionescu, I., Walters, M. C., Lubin, B. H., Gluckman, E. (2003). Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood 101: 2137-2143 [Abstract] [Full Text]  
• La Nasa, G., Giardini, C., Argiolu, F., Locatelli, F., Arras, M., De Stefano, P., Ledda, A., Pizzati, A., Sanna, M. A., Vacca, A., Lucarelli, G., Contu, L. (2002). Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes. Blood 99: 4350-4356 [Abstract] [Full Text]  
• Li, C K, Chik, K W, Lam, C W K, To, K F, Yu, S C H, Lee, V, Shing, M M K, Cheung, A Y K, Yuen, P M P (2002). Liver disease in transfusion dependent thalassaemia major. Arch. Dis. Child. 86: 344-347 [Abstract] [Full Text]  
• Battaglia, M., Andreani, M., Manna, M., Nesci, S., Tonucci, P., Persini, B., della Cuna, G. R., Nocera, A., Gorski, J., Lucarelli, G., De Palma, R. (1999). Coexistence of Two Functioning T-Cell Repertoires in Healthy Ex-Thalassemics Bearing a Persistent Mixed Chimerism Years After Bone Marrow Transplantation. Blood 94: 3432-3438 [Abstract] [Full Text]  
• Matthews, D. C., Martin, P. J., Nourigat, C., Appelbaum, F. R., Fisher, D. R., Bernstein, I. D. (1999). Marrow Ablative and Immunosuppressive Effects of 131I-Anti-CD45 Antibody in Congenic and H2-Mismatched Murine Transplant Models. Blood 93: 737-745 [Abstract] [Full Text]  
• Angelucci, E., Giovagnoni, A., Valeri, G., Paci, E., Ripalti, M., Muretto, P., McLaren, C., Brittenham, G. M., Lucarelli, G. (1997). Limitations of Magnetic Resonance Imaging in Measurement of Hepatic Iron. Blood 90: 4736-4742 [Abstract] [Full Text]  
• Di Marco, V., Iacono, O. L., Almasio, P., Ciaccio, C., Capra, M., Rizzo, M., Malizia, R., Maggio, A., Fabiano, C., Barbaria, F., Craxi, A. (1997). Long-Term Efficacy of alpha -Interferon in beta -Thalassemics With Chronic Hepatitis C. Blood 90: 2207-2212 [Abstract] [Full Text]  
• Angelucci, E., Muretto, P., Lucarelli, G., Ripalti, M., Baronciani, D., Erer, B., Galimberti, M., Giardini, C., Gaziev, D., Polchi, P., the Italian Cooperative Group for Phlebotomy Treat, (1997). Phlebotomy to Reduce Iron Overload in Patients Cured of Thalassemia by Bone Marrow Transplantation. Blood 90: 994-998 [Abstract] [Full Text]  
• Olivieri, N. F., Brittenham, G. M. (1997). Iron-Chelating Therapy and the Treatment of Thalassemia. Blood 89: 739-761 [Full Text]  
• Walters, M. C., Patience, M., Leisenring, W., Eckman, J. R., Scott, J. P., Mentzer, W. C., Davies, S. C., Ohene-Frempong, K., Bernaudin, F., Matthews, D. C., Storb, R., Sullivan, K. M. (1996). Bone Marrow Transplantation for Sickle Cell Disease. NEJM 335: 369-376 [Abstract] [Full Text]  
• Issaragrisil, S., Visuthisakchai, S., Suvatte, V., Tanphaichitr, V. S., Chandanayingyong, D., Schreiner, T., Kanokpongsakdi, S., Siritanaratkul, N., Piankijagum, A. (1995). Transplantation of Cord-Blood Stem Cells into a Patient with Severe Thalassemia. NEJM 332: 367-369 [Full Text]  
• Splendiani, G., Tozzo, C., Mazzarella, V., Casciani, C. U., Lucarelli, G., Clift, R., Angelucci, E., Cazzola, M., Locatelli, F., De Stefano, P., Olivieri, N. F., Nathan, D. G., Cohen, A. R. (1995). Deferoxamine in Thalassemia Major. NEJM 332: 270-273 [Full Text]  
• Brittenham, G. M., Griffith, P. M., Nienhuis, A. W., McLaren, C. E., Young, N. S., Tucker, E. E., Allen, C. J., Farrell, D. E., Harris, J. W. (1994). Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia Major. NEJM 331: 567-573 [Abstract] [Full Text]  
• Olivieri, N. F., Nathan, D. G., MacMillan, J. H., Wayne, A. S., Liu, P. P., McGee, A., Martin, M., Koren, G., Cohen, A. R. (1994). Survival in Medically Treated Patients with Homozygous {beta}-Thalassemia. NEJM 331: 574-578 [Abstract] [Full Text]  
• Dover, G. J., Valle, D. (1994). Therapy for {beta}-Thalassemia -- A Paradigm for the Treatment of Genetic Disorders. NEJM 331: 609-610 [Full Text]  
• Weatherall, D.J. (1993). The Treatment of Thalassemia -- Slow Progress and New Dilemmas. NEJM 329: 877-879 [Full Text]